{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:52:12Z","timestamp":1777866732945,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T00:00:00Z","timestamp":1254787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T00:00:00Z","timestamp":1254787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"abstract":"<jats:p>A prospective randomised placebo-controlled double-blind study was designed to investigate whether topical terbinafine 1% solution is an effective treatment for subjects with pityriasis versicolor. The intention-to-treat poulation consisted of 110 subjects. The number of subjects who received terbinafine 1% solution was 76 and the number who received placebo was 34; treatments were given twice a day for 1 week. The primary efficacy variables were categorised at weeks 1, 2, 4 and 8. Eight weeks after the start of therapy, 81% of the subjects using terbinafine solution and 41% of those receiving placebo had a negative mycological examination (p &lt; 0.001). A clinical effect of treatment was recorded in 72% of the subjects using terbinafine 1% solution and 26% of those receiving placebo (p &lt; 0.001). We conclude that terbinafine 1% solution is an effective and safe local treatment modality for pityriasis versicolor.<\/jats:p>","DOI":"10.1159\/000246179","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T07:08:20Z","timestamp":1254899300000},"page":"22-24","source":"Crossref","is-referenced-by-count":21,"title":["The Efficacy of a Topical Application of Terbinafine 1% Solution in Subjects with Pityriasis versicolor: A Placebo-Controlled Study"],"prefix":"10.1159","author":[{"given":"B.J.","family":"Vermeer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.C.G.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,10,6]]},"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/246179","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000246179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:14:14Z","timestamp":1777540454000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000246179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000246179","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,6]]}}}